BioLife Solutions (NASDAQ:BLFS) announced results for Q1 2014. Revenue of $2.1M was about 4% lower yoy although excluding $609k in non-recurring licensing revenue booked in Q1 2013, total revenue growth was 33%. Even more importantly growth in product revenue, which will be the long-term driver of the top-line (as opposed to contract manufacturing revenue), increased by 47% from the $770k booked in Q1 2013. Product revenue of $1.13M was just shy of the $1.21M record set in Q4 2013 and marks the third straight quarter above $1M. Management reiterated product sales growth guidance of 25% - 35% for the full year.
Meanwhile, contract manufacturing grew 20% to $933k. Unfortunately contract manufacturing revenue, which has buoyed the top-line over
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|